Nuvalent (NUVL) Cash & Equivalents (2020 - 2026)
Nuvalent (NUVL) posted Cash & Equivalents of $159.7 million for Q1 2026, down 38.97% on a QoQ basis from $261.7 million in Q4 2025, and up 32.19% year-over-year from $120.8 million in Q1 2025.
Nuvalent (NUVL) Cash & Equivalents (2020 - 2026) Analysis & Trends
Nuvalent's Cash & Equivalents history runs 7 years deep, the most recent figure standing at $159.7 million for Q1 2026.
- Quarterly Cash & Equivalents rose 32.19% year-over-year to $159.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $159.7 million (up 32.19% YoY) and the FY2025 annual result came in at $261.7 million, up 79.66% from the prior year.
- Cash & Equivalents was $159.7 million for Q1 2026 at Nuvalent, down from $261.7 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $369.2 million in Q3 2024 and bottomed at $67.3 million in Q1 2022.
- A 5-year average of $158.0 million and a median of $120.8 million in 2025 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2024 — Cash & Equivalents surged 317.54% — and 2025, when it slumped 68.65%.
- Nuvalent's Cash & Equivalents stood at $241.8 million in 2022, then jumped by 38.7% to $335.4 million in 2023, then slumped by 56.56% to $145.7 million in 2024, then jumped by 79.66% to $261.7 million in 2025, then sank by 38.97% to $159.7 million in 2026.
- Business Quant data shows NUVL's Cash & Equivalents at $159.7 million in Q1 2026, $261.7 million in Q4 2025, and $115.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 82.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.49 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.96 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 3.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 440.94 Mn |
| 10 | Nuvalent | 9.75 Bn | 9.75 Bn | - | 159.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 159.73 Mn |
| Dec 31, 2025 | 261.75 Mn |
| Sep 30, 2025 | 115.75 Mn |
| Jun 30, 2025 | 127.47 Mn |
| Mar 31, 2025 | 120.84 Mn |
| Dec 31, 2024 | 145.69 Mn |
| Sep 30, 2024 | 369.24 Mn |
| Jun 30, 2024 | 77.70 Mn |
| Mar 31, 2024 | 98.52 Mn |
| Dec 31, 2023 | 335.39 Mn |
| Sep 30, 2023 | 88.43 Mn |
| Jun 30, 2023 | 70.87 Mn |
| Mar 31, 2023 | 90.12 Mn |
| Dec 31, 2022 | 241.81 Mn |
| Sep 30, 2022 | 239.06 Mn |
| Jun 30, 2022 | 75.92 Mn |
| Mar 31, 2022 | 67.27 Mn |
| Dec 31, 2021 | 68.53 Mn |
| Sep 30, 2021 | 245.89 Mn |
| Dec 31, 2020 | 10.33 Mn |